Active, not recruitingPHASE1, PHASE2NCT05664243
A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma
Studying Glioblastoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- In8bio Inc.
- Principal Investigator
- Louis B Nabors, MDUniversity of Alabama at Birmingham
- Intervention
- Autologous genetically modified gamma-delta T cells(biological)
- Enrollment
- 4 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2025
Study locations (5)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- University of Louisville Hospital/James Graham Brown Cancer Center, Louisville, Kentucky, United States
- Cleveland Clinic, Cleveland, Ohio, United States
- Ohio State University Wexner Medical Center- James Cancer Center, Columbus, Ohio, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05664243 on ClinicalTrials.govOther trials for Glioblastoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07501559A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM)Jecho Biopharmaceuticals Co., Ltd.
- RECRUITINGPHASE2NCT07326566Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIIIBlack Diamond Therapeutics, Inc.
- RECRUITINGPHASE1NCT07464925A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade GliomaTetragon Biosciences Ltd
- RECRUITINGNCT07411690Analysis of Cerebrospinal Fluid Leakage After Surgery for Intracranial TumorsMedical University of Warsaw
- RECRUITINGPHASE1NCT07480941Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade GliomaBeijing Biotech
- RECRUITINGPHASE2NCT07225621Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed GlioblastomaAlpheus Medical, Inc.
- RECRUITINGPHASE1, PHASE2NCT073912155G-PEARL: Paxalisib in Malignant Brain TumoursInstitute of Cancer Research, United Kingdom
- RECRUITINGNANCT07426848OT SMILE: Occupational Therapy Group Intervention for Primary Brain Tumour PatientsRoyal College of Surgeons, Ireland